The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent

Ke Tang; Can Luo; Yan Li; Chenshu Lu; Wanqi Zhou; Haihong Huang; Xiaoguang Chen

doi:10.1371/journal.pone.0101889

Loading metrics

Open Access

Peer-reviewed

Research Article

The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent

Ke Tang,

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Can Luo,

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Yan Li,

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Chenshu Lu,

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Wanqi Zhou,

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Haihong Huang ,

* E-mail: joyce@imm.ac.cn (HH); chxg@imm.ac.cn (XC)

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯
Xiaoguang Chen

* E-mail: joyce@imm.ac.cn (HH); chxg@imm.ac.cn (XC)

Affiliation State Key Laboratory of Bioactive Substances and Functions of Nature Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
⨯

The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent

Ke Tang,
Can Luo,
Yan Li,
Chenshu Lu,
Wanqi Zhou,
Haihong Huang,
Xiaoguang Chen

Published: July 8, 2014
https://doi.org/10.1371/journal.pone.0101889

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
HT29 cells
Is the Subject Area "HT29 cells" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Angiogenesis
Is the Subject Area "Angiogenesis" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.